Archive | heart failure RSS feed for this section

Impact of Hyponatremia Correction on the Risk for 30-Day Readmission and Death in Patients with Congestive Heart Failure

  The study objective was to compare the 30-day readmission rate and mortality between patients with heart failure who have persistent hyponatremia during hospitalization and patients who have their admission hyponatremia corrected before discharge. Methods This large retrospective cohort study included all adult patients admitted with a diagnosis of congestive heart failure to a tertiary-care […]

Read more
man holding chest and woman offering him water

To Supplement or Not: A Role for Antioxidant Vitamins in the Management of Heart Failure?

  There is an epidemic of heart failure occurring in advanced industrial nations. The number one diagnosis for payment by Medicare in the US is heart failure. Because heart failure is increasingly prevalent among the elderly, and because the population of individuals older than age 65 years is increasing rapidly in the US, patients with […]

Read more
Pathophysiologic factors leading to alterations in levels of biomarkers used in the assessment and management heart failure. Note procalcitonin is not actually released from the heart, while NPs, ST2, and high-sensitivity troponin are released from the heart. NP = natriuretic peptide; NEP = neutral endopeptidase; hs = high-sensitivity.

Biomarkers for Heart Failure: An Update for Practitioners of Internal Medicine

Abstract Biomarkers have become an integral part of practicing medicine, especially in heart failure. The natriuretic peptides are commonly used in the evaluation of heart failure, but their role extends beyond diagnosis and includes risk stratification and management of heart failure patients. Newer biomarkers have arrived and are becoming part of routine care of heart […]

Read more
Dr. Joseph S. Alpert

Heart Failure with Preserved Ejection Fraction (video)

Heart failure is usually broken down into two categories: heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). Hospitalizations for both are comparable, but HFpEF hospitalizations are expected to increase in the future. Consequently, there is a need for better treatments for HFpEF patients. In this video, AJM Editor-in-chief […]

Read more

Contemporary Role for Digoxin in Heart Failure

Physicians who see patients with heart failure (HF) with reduced ejection fraction (HFrEF) must deal with these patients’ symptoms of exercise intolerance, fatigue, and congestion that often lead to hospitalization, despite correct application of guideline-recommended life-prolonging therapies. The result is the current cost of $30 billion spent annually for HF hospitalizations alone, and given the […]

Read more

Digoxin and 30-day All-cause Hospital Admission in Older Patients with Chronic Diastolic Heart Failure

New findings from the DIG trial… Abstract Background In the main Digitalis Investigation Group (DIG) trial, digoxin reduced the risk of 30-day all-cause hospitalization in older systolic heart failure patients. However, this effect has not been studied in older diastolic heart failure patients. Methods In the ancillary DIG trial, of the 988 patients with chronic […]

Read more